Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty
- 31 July 1996
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 132 (1) , 23-29
- https://doi.org/10.1016/s0002-8703(96)90386-5
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica.Circulation, 1994
- Clinical trials of restenosis after coronary angioplasty.Circulation, 1991
- Restenosis after coronary angioplasty: An overviewJournal of the American College of Cardiology, 1991
- Restenosis following coronary angioplastyAmerican Heart Journal, 1990
- Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplastyJournal of the American College of Cardiology, 1989
- Enzyme-linked immunosorbent assay of lipoprotein(a) in serum and cord bloodClinica Chimica Acta; International Journal of Clinical Chemistry, 1988
- Long-Term Follow-up after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1987
- Studies on the mechanism of action of probucolThe American Journal of Cardiology, 1986
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood instituteThe American Journal of Cardiology, 1984
- Nonoperative Dilatation of Coronary-Artery StenosisNew England Journal of Medicine, 1979